MET and non-small cell lung carcinoma: We demonstrated that combinations of MET with anti-PD-1/PD-L1 effectively stimulate an anti-tumor immune response by activating key cytosolic DNA sensors and enhancing pro-immune characteristics, particularly in LKB1 mutant NSCLC tumors.